The median duration of reported cough at study entry was 52 weeks and it was severe enough in more than half of participants that it warranted treatment.
Being 64 years or younger, being male, having underwent a thoracotomy, and using adjuvant therapy were all associated with a greater risk for persistent opioid use.
More frequent postsurgical surveillance is not associated with improved survival in non-small cell lung cancer.
Annual number of deaths from lung cancer are expected to continue to decrease despite the growth and aging of the US population.
The FDA has approved Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC.
The FDA has approved Keytruda in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of patients with metastatic squamous NSCLC.
Both overall and progression-free survival were longer with durvalumab vs placebo.
To investigate the association between this commonly used antihypertensive class and lung cancer, researchers conducted a population based cohort study involving 992,061 patients from the United Kingdom Clinical Practice Research Datalink.
Patients who had video-assisted thoracoscopic surgery were less likely to use opioids long term.
Tobacco control could prevent more cancer deaths than any other strategy.
Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.
Most patients with metastatic non-small cell lung cancer who received targeted therapy based on plasma result achieved clinical response.
In individuals aged 18 to 35, California has had larger drops in smoking initiation, intensity, and higher rates of quitting.
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLCOctober 19, 2018
Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.
Longer progression-free survival was significantly longer in patients with ALK-positive disease who did not previously take an ALK inhibitor.
Classifier integrates relative abundance of 2 plasma proteins with clinical risk prediction model for lung nodules.
The approval was based on data from the ARCHER 1050 open-label, active controlled study which randomized patients with unresectable, metastatic NSCLC to treatment with either dacomitinib (N=227) or gefitinib (N=225).
Salvage treatment for recurrence of early-stage non-small cell lung cancer after initial treatment with stereotactic ablative radiotherapy improved patient survival.
LOXO-292 is being evaluated in the ongoing Phase 1/2 LIBRETTO-001 clinical trial.
Serving patients' specific needs, such as referral to socioeconomic support, can improve care.
High-quality diet linked to reduced risk of overall and cancer-specific mortality vs poor-quality diet.
Physicians universally recommended lung cancer screening and rarely discuss harms.
Screening for small cell lung cancer using low-dose computed tomography had no effect on outcomes for patients.
Although screening for lung cancer with low-dose computed tomography has demonstrated a reduction in mortality, some experts say the benefits do not outweigh the potential harms.
As lung cancer screening disseminates into clinical practice, efforts designed to target black men should be prioritized.
The median OS was not reached at the time of the data cut-off in the pembrolizumab plus chemotherapy arm and was 11.3 months for those in the chemotherapy arm.
Data showed that 12% responded to treatment based on assessment by a Blinded Independent Central Review, regardless of PD-L1 expression; 11% had a partial response, and 1 patient had a complete response (0.9%).
Compared with routine genetic testing, there was no improvement in unadjusted mortality rate in non-small cell lung cancer.
From 2000 to 2015, individuals without insurance or usual care were less likely to have undergone cancer screening.
Risk score based on panel of four circulating protein biomarkers.